IM Cannabis (IMCC) Cash from Operations Growth (3y) (2023 - 2026)
IM Cannabis (IMCC) Cash from Operations Growth (3y) (2023 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 34.90% |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | -9.94% |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -10.80% |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 7.32% |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | -26.33% |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 46.81% |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 27.85% |
| 10 | IM Cannabis | 591,792.44 | -193,562.09 | 1.03 Mn | 68.84% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 68.84% |
| Dec 31, 2025 | 53.74% |
| Sep 30, 2025 | -82.79% |
| Jun 30, 2025 | 33.56% |
| Mar 31, 2025 | 34.21% |
| Dec 31, 2024 | -40.87% |
| Sep 30, 2024 | 29.22% |
| Jun 30, 2024 | 27.22% |
| Mar 31, 2024 | 57.67% |
| Dec 31, 2023 | 26.93% |
| Sep 30, 2023 | 65.86% |
| Jun 30, 2023 | -30.79% |
| Mar 31, 2023 | -44.12% |